IRB Barcelona and the Graduate School of Pharmaceutical Sciences of the Tohoku University in Japan have signed a new academic exchange agreement. In August, the Dean of the Japanese institution and IRB Barcelona Director Joan J. Guinovart endorsed a long-standing collaboration between scientists at the two centres.
Extensive impact of Natàlia Carulla’s work at IRB Barcelona on a new method through which to study neuron death in Alzheimer’s disease.
Published in PNAS, the study addresses the effects of an amyloid protein aggregate that has the capacity to perforate the neuronal cell membrane—a process that may cause the toxicity of these aggregates and that could be validated as a therapeutic target.
Link to La Vanguardia:
Researchers at IRB Barcelona describe for the first time how to prepare a specific type of aggregate of the amyloid-beta protein with the ability to perforate the cell membrane.
What causes neuron death and the subsequent cognitive decline in Alzheimer´s disease is still unknown.
IRB Barcelona researchers publish a review article on the emerging field of drug transporters that have the capacity to reach the brain more efficiently.
IRB Barcelona is one of the few centres worldwide with a specific line of research devoted to this field, which brings together chemistry, pharmacy and biomedicine.
The article appears on the cover of the journal Chemical Society Reviews.
“I’m still enthusiastic. Just a bit less naïve.” Salva Guardiola, PhD student in Ernest Giralt’s Design, Synthesis, and Structure of Peptide and Proteins Lab, has just published his first paper in ChemBioChem. And in the life of a researcher, the first article is never forgotten, it leaves a mark the rest of your career.
The idea Salva and his colleagues had was to design and test a peptide,...
The medical portal ""El Médico Hospitaliario" and other media report on IRB Barcelona's research on compounds able to act against EGF, a little-explored cancer target.
The study has been published in ChemBioChem.
The molecules synthesized by Ernest Giralt’s lab at IRB Barcelona bind a key protein in cancer that has received little attention as a therapeutic target.
The long-term goal is to provide a new chemotherapy treatment.
After seven intense years in Ernest Giralt’s lab, Laura Nevola (Benevento, Italy, 1980) is ready to undertake a new challenge in her career. “It’s time to fly on my own,” she says.
This award recognizes his thesis, which addressed the use of shuttle peptides to overcome the blood-brain barrier.